Anifrolumab
Monoclonal antibody / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Anifrolumab?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus.[5][7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.[medical citation needed]
Quick Facts Monoclonal antibody, Type ...
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Interferon α/β receptor |
Clinical data | |
Trade names | Saphnelo |
Other names | MEDI-546, anifrolumab-fnia |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category | |
Routes of administration | Intravenous |
Drug class | type I interferon receptor antagonist (IFN) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6444H9964N1712O2018S44 |
Molar mass | 145119.20 g·mol−1 |
Close
Anifrolumab was approved for medical use in the United States in July 2021,[5][8][9][10][11] and in the European Union in February 2022.[6] The U.S. Food and Drug Administration considers it to be a first-in-class medication.[12]